If the genome-editing system CRISPR-Cas9 is biology’s precise, disciplined, Swiss army knife, its march toward the clinic is more like the roller coaster from hell. One moment it’s riding high with the promise of curing devastating genetic diseases, then its prospects plummet after the discovery of previously unsuspected risks, and the next moment it turns out those risks are either overblown or avoidable. Buy another ticket and get back on board.

On Thursday, scientists led by one of the world’s foremost gene therapy experts reported a way around one of the more worrisome obstacles: that CRISPR’d cells might be prone to becoming cancerous, as two 2018 studies suggested.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • How long before this mouse fix for CRISPR is incorporated into human trials? Sangamo’s ZFN’s already edit without p53 mutation. They are in the clinic for beta-thalassemia and sickle cell both partnered with Sanofi.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy